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Objective: δ-Opioid receptors are involved in the cardioprotective effect of ischemic
preconditioning. This study was designed (1) to assess the protective capacities of
ischemic preconditioning and the synthetic δ-opioid receptor agonist D-Ala2-D-
Leu5 enkephalin (DADLE) in a functionally oriented experimental model of
ischemia and reperfusion and (2) to assess whether the effects of both protective
measures are similarly blocked by naloxone, a nonspecific δ-opioid receptor antag-
onist.
Methods: Sixty-four isolated working rat hearts were subjected to 45 minutes of
hypothermic ischemia at 30°C followed by 25 minutes of normothermic reperfu-
sion. Rats were pretreated with DADLE (1 mg/kg body weight intravenously),
naloxone (3 mg/kg body weight intravenously), or a combination thereof within 60
minutes before onset of isolated heart perfusion. During the preischemic perfusion
period, 8 hearts per group were preconditioned by one cycle of 5 minutes of nor-
mothermic global ischemia and subsequent reperfusion whereas another 8 served as
nonpreconditioned controls. The postischemic functional recovery of hearts and
their creatine kinase leakage were determined. 
Results: Pretreatment with DADLE and ischemic preconditioning improved the
postischemic recovery of aortic flow when compared with nonpreconditioning
(57.7% ± 4.0% and 60.8% ± 4.3% vs 40.0% ± 4.2% of preischemic baseline value,
P < .001). Combined pretreatment with DADLE before ischemic preconditioning
afforded additional aortic flow recovery compared with pretreatment with DADLE
alone (68.6% ± 3.3% vs 57.7% ± 4.0% of preischemic baseline value; P = .038).
With combined pretreatment, early postischemic creatine kinase release was lower
than control in hearts without pretreatment (0.48 ± 0.11 vs 0.80 ± 0.12 IU/5 min-
utes per heart; P = .001). Naloxone abolished the beneficial functional effects of
pretreatment with DADLE and ischemic preconditioning.
Conclusions: Pharmacologic activation of δ-opioid receptors affords improvement
of functional protection in isolated working rat hearts similar to that conferred by
classic ischemic preconditioning. The combination of both pretreatments reduces
ischemic cellular damage and further adds to postischemic functional recovery.
These changes are reversed by naloxone, an observation providing evidence that
ischemic preconditioning involves signaling through opioid receptors.
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Among the current strategies to improveintraoperative cardiac protection, ischemicpreconditioning has generated great interestbecause of its efficacy across a wide rangeof experimental models and animalspecies.1,2 The search for pharmacologic
alternatives of the classic ischemic-type stimulus revealed that
direct activation of δ1- and/or δ2-opioid receptor subtypes may
similarly trigger the preconditioning pathway.3,4 Interestingly,
signaling via δ-opioid receptors also appears to be involved in
natural mammalian hibernation biology, which parallels the
altered cardiac physiology noted with hypothermia. This con-
clusion was derived from observations that (1) pretreatment
with δ-opioid receptor agonists such as D-Ala2-D-Leu5
enkephalin (DADLE) induces hibernation-like changes in
nonhibernators and that (2) hibernation can be reversed by
opiate antagonists.5,6 On the basis of this coincidence, recent
reports in fact suggest that natural hibernation and precondi-
tioning share a common protective pathway via opioid recep-
tor signaling and subsequent activation of the potassium
channel.7 This and other studies on ischemic preconditioning
and direct, drug-induced δ-opioid receptor activation investi-
gated the range of applications in various clinically relevant
fields of myocardial protection.8-11 Commonly, study end
points included markers of tissue damage such as creatine
kinase leakage and infarct size with functional aspects being
addressed by nonworking isolated heart preparations. In these
models, however, hearts do not perform external work and
their oxygen requirements are considerably less than those of
the ejecting heart in vivo.12 This may limit their relevance in
predicting the true postischemic capabilities to restore cardiac
function, which remains the decisive quality parameter of any
protective measure under investigation. We therefore used the
isolated working rat heart model, which more closely resem-
bles the conditions of the beating heart in situ. Four aspects
relevant to the understanding of possible coincidence between
ischemic preconditioning and drug-induced δ-opioid receptor
activation were addressed under functional aspects: (1) Does
pharmacologic activation of the δ-opioid receptor by pretreat-
ment of the intact animal with DADLE improve cardiac func-
tion during reperfusion after hypothermic ischemia? (2) If yes,
to what extent does this alteration compare with that conferred
by classic ischemic preconditioning? (3) Does the nonselec-
tive opioid receptor antagonist naloxone block effects of both
pretreatment with DADLE and ischemic preconditioning? (4)
Do both protective measures act synergistically?
Materials and Methods
Perfusion Methodology 
The isolated working rat heart model was used for the purpose of this
study.13 Hearts were obtained from male Wistar rats (300-400 g,
Charles River, Inc, Sulzfeld, Germany). Animals were kept in a
pathogen-free environment and had free access to food and water
before the experiments. All animals received humane care in compli-
ance with the “Principles of Laboratory Animal Care” formulated by
the National Society for Medical Research and the “Guide for the
Care and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources, National Research Council, and pub-
lished by the National Academy Press, revised 1996.
Rats received an injection of sodium heparin (100 IU/100 g body
weight intraperitoneally). After 15 minutes, the animals were anes-
thetized by inhalation of diethyl ether. Then, each heart was rapidly
excised and placed in ice-cold saline solution. The aorta was cannu-
lated and Langendorff perfusion was initiated at a pressure of 90 cm
H2O with modified Krebs-Henseleit buffer containing (in millimoles
per liter) NaCl, 118; KH2PO4, 1.2; KCl, 4.9; CaCl2, 3; MgSO4, 1.2;
NaHCO3, 25; and glucose, 11.1. The perfusion fluids were filtered
through a 5-µm porosity filter to remove any particulate matter. The
perfusate was aerated with a mixture of 95% oxygen and 5% carbon
dioxide (pH 7.4) and the perfusate temperature was kept at 37°C.
During the time of Langendorff perfusion the left atrium was cannu-
lated for conversion of the preparation to the working heart mode,
which was achieved by stopping aortic perfusion and starting left
atrial perfusion at a filling pressure of 20 cm H2O. Under these con-
ditions the perfusate was ejected spontaneously at a rate of approxi-
mately 40 mL/min through the aortic cannula against a hydrostatic
pressure of 90 cm H2O. Hearts producing less than 37 mL/min aortic
flow were excluded from the study. Aortic flow was measured by
timed collection of the ejected perfusate in a graduated cylinder.
Likewise, coronary flow was measured by timed collection of the
coronary effluent. Cardiac output was calculated from the sum of aor-
tic and coronary flow. The perfusate was not recycled. After the mea-
surement of aortic flow, a Millar Mikro-Tip catheter connected to a
pressure transducer (Millar Instruments, Inc, Houston, Tex) was
inserted into the left ventricle through a rubber-sealed side port of the
left atrial cannula for 1 minute of data acquisition. The left ventricu-
lar pressure signal was recorded and processed online by an analog-
digital converter (Plugsys; Hugo Sachs Electronic, March, Germany).
Data processing was performed by an 80386 IBM-compatible per-
sonal computer equipped with standard laboratory software
(Haemodyn, Hugo Sachs Electronic).
Experimental Protocol 
After cannulation of the aorta, the heart was allowed to stabilize
for 10 minutes in the Langendorff perfusion mode (Figure 1). After
conversion to the working heart mode, the preparation was per-
fused for 15 minutes. Contractile function was measured and
recorded. Then, hearts undergoing ischemic preconditioning (8
hearts per experimental group) were subjected to 5 minutes of
global normothermic ischemia, followed by 5 minutes of
Langendorff reperfusion. Hearts not undergoing preconditioning
(8 hearts per experimental group) underwent 10 minutes of
Langendorff perfusion instead. 
Thereafter, all hearts were subjected to 45 minutes of global
unprotected hypothermic ischemia at 30°C by stopping the perfu-
sion and submerging the heart in perfusate at the appropriate tem-
perature. Then, hearts were reperfused for 10 minutes in the
Langendorff mode before the perfusion system was converted to
the working heart mode for 15 minutes. Functional recovery was
reassessed at the end of this period. Creatine kinase (CK) activity
was measured in the coronary effluent collected during the initial
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5-minute period of the preischemic working heart mode and also
during the initial 5-minute periods of postischemic Langendorff
and working heart perfusion periods. A standard enzymatic test
based on spectrophotometric measurement of the amount of nicotin-
amide adenine dinucleotide phosphate was used (Granutest 2.5;
Merck, Darmstadt, Germany).14
Experimental Groups 
A total of 64 rats were assigned randomly to 1 of 4 experimental
groups. Each group was divided into 2 subgroups, comprising 8
experiments with ischemic preconditioning and 8 experiments
without. Animals in group 1 served as controls without pretreat-
ment with DADLE or naloxone. Animals in group 2 received an
TABLE 1.  Preischemic functional baseline data
Aortic flow Coronary flow Cardiac output Maximum LVDP dP/dtmax Heart rate 
Experimental group IPC (mL/min) (mL/min) (mL/min) (mm Hg) (mm Hg/s2) (beats/min)
1 – 38.8 ± 1.0 17.2 ± 1.4 55.0 ± 2.1 150 ± 7 3993 ± 607 294 ± 19
(Control) + 39.5 ± 1.4 16.7 ± 1.9 55.5 ± 2.0 140 ± 13 3783 ± 818 275 ± 18
2 – 39.0 ± 1.1 19.3 ± 0.8 58.2 ± 2.4 149 ± 5 3186 ± 466 282 ± 20
(DADLE) + 39.0 ± 1.9 18.8 ± 1.3 58.0 ± 2.1 151 ± 5 3287 ± 547 292 ± 10
3 – 39.5 ± 1.8 19.3 ± 1.0 59.0 ± 2.3 151 ± 5 3578 ± 288 291 ± 21
(Naloxone) + 39.5 ± 2.3 18.9 ± 0.9 58.5 ± 2.7 151 ± 5 3587 ± 198 288 ± 15
4 – 40.0 ± 1.2 19.0 ± 1.0 58.5 ± 2.7 153 ± 3 3268 ± 195 271 ± 7
(DADLE + naloxone) + 39.1 ± 1.0 18.6 ± 0.9 58.2 ± 2.5 157 ± 4 3557 ± 153 278 ± 8
LVDP, Left ventricular developed pressure; IPC, ischemic preconditioning; DADLE, D-Ala2-D-Leu5 enkephalin.
TABLE 2.  Postischemic functional recovery rates during reperfusion following 45 minutes of hypothermic ischemia at 30°C
(in % of preischemic values)
Experimental group IPC Aortic flow (%) Coronary flow (%) Cardiac output (%) Maximum LVDP (%) dP/dtmax (%) Heart rate (%)
1 – 40.0 ± 4.2 81.3 ± 12.6 50.3 ± 6.4 85.6 ± 8.0 79.2 ± 12.5 95.4 ± 6.4
(Control) + 60.8 ± 4.3 91.0 ± 8.7 69.2 ± 3.9 92.7 ± 5.1 87.8 ± 13.6 93.1 ± 7.7
2 – 57.7 ± 4.0 88.2 ± 7.6 67.1 ± 4.5 88.2 ± 7.6 77.0 ± 9.8 88.5 ± 5.0
(DADLE) + 68.6 ± 3.3* 88.6 ± 9.2 74.1 ± 3.1 91.7 ± 4.8 84.0 ± 8.3 88.0 ± 5.6
3 – 39.2 ± 3.3 83.7 ± 4.8 53.7 ± 2.2 88.4 ± 3.4 76.7 ± 3.3 86.1 ± 5.9
(Naloxone) + 46.1 ± 5.6 92.2 ± 6.7 61.5 ± 5.7 91.1 ± 3.7 78.1 ± 5.0 87.8 ± 3.5
4 – 39.1 ± 5.2 82.3 ± 4.5 52.2 ± 4.4 87.5 ± 2.4 84.1 ± 3.6 89.4 ± 5.5
(DADLE + naloxone) + 42.3 ± 4.3 89.5 ± 8.0 58.8 ± 2.8 88.4 ± 2.5 76.7 ± 6.3 86.6 ± 9.4
LVDP, Left ventricular developed pressure. 
*P = .038 versus “control IPC+”; mean values of recovery rates in aortic flow in groups “control IPC+,” “DADLE IPC–,” and “DADLE IPC+” were different
from group means of all other groups (P < .001).
TABLE 3. Creatine kinase leakage during the preischemic and postischemic perfusion periods
Preischemic, working heart Postischemic, Langendorff Postischemic, working heart
Experimental group IPC (IU/5 min/heart) (IU/5 min/heart) (IU/5 min/heart)
1 – 0.25 ± 0.03 0.80 ± 0.12 0.31 ± 0.08
(Control) + 0.23 ± 0.04 0.57 ± 0.07 0.44 ± 0.11
2 – 0.26 ± 0.03 0.58 ± 0.07 0.37 ± 0.08
(DADLE) + 0.27 ± 0.03 0.48 ± 0.11* 0.36 ± 0.07
3 – 0.23 ± 0.03 0.75 ± 0.24 0.39 ± 0.12
(Naloxone) + 0.23 ± 0.03 0.61 ± 0.11 0.39 ± 0.11
4 – 0.22 ± 0.04 0.67 ± 0.16 0.46 ± 0.21
(DADLE + naloxone) + 0.22 ± 0.05 0.64 ± 0.16 0.45 ± 0.24
IPC, Ischemic preconditioning; DADLE, D-Ala2-D-Leu5 enkephalin.
*P = .001 versus control, IPC–.
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injection of DADLE, 1 mg/kg body weight (Multiple Peptide
Systems Inc, San Diego, Calif), during a 5-minute period by direct
puncture of the tail vein 60 minutes before they were put to death
and subsequent isolated heart perfusion was begun. Animals in
group 3 received an intravenous injection of naloxone, 3 mg/kg
body weight, 30 minutes before being put to death. Rats in group
4 received an injection of DADLE, 1 mg/kg body weight, by direct
puncture of the tail vein, followed by injection of naloxone, 3
mg/kg body weight, 60 minutes before being put to death.
Expression of Results
All results are expressed as mean ± standard deviation.
Preischemic values of cardiac function, including aortic flow,
coronary flow, cardiac output, maximum left ventricular developed
pressure, maximum rate of pressure rise (dP/dtmax), heart rate,
and coronary flow, are expressed in terms of absolute values, and
indices of postischemic function are given as a percentage of their
individual preischemic values. CK leakage in the coronary efflu-
ent, measured during the preischemic and postischemic perfusion
periods, is expressed as international units per 5 minutes per heart. 
Statistical Analysis 
One-way analysis of variance with Bonferroni corrected t test (for mul-
tiple comparisons) was used to detect differences between groups. 
Results 
Table 1 shows the absolute values for preischemic cardiac
function. Differences observed between group means could
be due to chance (P > .2). Figure 2 and Table 2 show the
recovery of cardiac function after 45 minutes of global
hypothermic ischemia at 30°C. Both pretreatment with
DADLE and ischemic preconditioning improved the recov-
ery of aortic flow when compared with untreated controls
(57.7% ± 4.0% and 60.8% ± 4.3% vs 40.0% ± 4.2%; P <
.001). Pretreatment with DADLE before ischemic precondi-
tioning further enhanced aortic flow recovery (68.6% ±
3.3%) above values obtained by ischemic preconditioning
alone (P = .038) and DADLE alone (P < .001). A similar pat-
tern was observed with regard to cardiac output. The effects
of ischemic preconditioning, DADLE, and the combination
thereof on recovery rates of aortic flow and cardiac output
were counteracted by additional naloxone pretreatment.
Analysis of the other postischemic functional parameters
including heart rate, maximum left ventricular developed
pressure, dP/dtmax, and coronary flow revealed differences
among the study groups that could be due to chance (P > .2).
There was no important difference in the CK leakage from
preischemic hearts among any of the experimental groups (P
> .2) (Table 3). The immediate postischemic CK release dur-
ing reperfusion in the Langendorff mode was increased in all
hearts. During this phase, lowest CK values were measured
after pretreatment with DADLE combined with ischemic pre-
conditioning (P = .001 vs untreated controls). In all groups
involving additional pretreatment with naloxone, CK leakage
did not differ markedly from that of untreated controls.
Subsequent reperfusion in the working heart mode was fol-
lowed by a decrease in the CK leakage in all experimental
groups. No group-dependent differences were found during
this period (P > .2).
Discussion
Four results emerge from this study: (1) Pharmacologic acti-
vation of the δ-opioid receptor by use of the synthetic opioid
receptor agonist DADLE improves the postischemic aortic
flow recovery of isolated working rat hearts exposed to 45
minutes of hypothermic ischemia at 30°C. (2) This improve-
Figure 1. Experimental protocol of isolated heart perfusion. L, Langendorff perfusion; W, working heart perfusion;
IPC, ischemic preconditioning. The upper scheme represents the protocol with ischemic preconditioning by one
cycle of 5 minutes of global normothermic ischemia followed by 5 minutes of normothermic reperfusion before
subsequent global hypothermic ischemia (45 minutes at 30°C). The lower scheme represents the perfusion pro-
tocol without ischemic preconditioning and 10 minutes of Langendorff perfusion instead. Myocardial function
and creatine kinase (CK) leakage were assessed at the indicated time points. 
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ment is similar in extent to that conferred by a standard proto-
col of ischemic preconditioning. (3) Effects of either treatment
can be blocked by the nonselective opiate receptor antagonist
naloxone, a finding further supporting the hypothesis that the
δ-opioid receptor is involved in signaling of ischemic precon-
ditioning. (4) Under selected experimental conditions, phar-
macologic preconditioning by pretreatment with DADLE and
ischemic preconditioning have additive beneficial effects with
regard to postischemic functional recovery. 
We have shown earlier that both a plasma fraction from
hibernating animals (hibernation induction trigger) and the
selective δ-opioid receptor agonist DADLE similarly
improve protection in animal models of multiorgan autoper-
fusion and cardioplegic arrest.15,16 The observation that opi-
oid receptor antagonists such as naloxone or naltrexone
reverse these changes supported the hypothesis that periph-
eral opioid receptors are involved in signal transduction
occurring during natural hibernation.17 Subsequent studies
in various experimental models revealed that natural and
“artificial” hibernation induction triggers such as DADLE
improve organ protection in experimental models relevant to
clinical cardiac surgery, including heart and lung transplan-
tation.8,18,19
Ischemic preconditioning, on the other hand, implies an
endogenous mechanism by which a brief period of ischemia
protects the tissues against adverse effects of a subsequent
prolonged ischemic interval.1 Since the first description of
this phenomenon by Murry and coworkers,1 protective capa-
bilities of ischemic preconditioning have been demonstrated
in a wide spectrum of animals and circumstances.20,21
Meanwhile, a variety of intracellular signaling pathways have
been implicated in the protective effect of ischemic precondi-
tioning. These include the activation of G protein–linked
phospholipase C–coupled receptors, tyrosine kinase path-
ways, protein kinase C, and the generation of reactive oxygen
species.22 Protection can be blocked at several stages, but due
to inherent high redundancy of the receptor systems involved,
alternative pathways may open up and preserve protection.
Above that, it appears that there is a threshold to trigger pre-
conditioning, which may vary depending on differential acti-
vation of adenosine, bradykinin, and also opioid receptors.23
Such a scheme would require that all receptor systems includ-
ing the opioid-coupled transduction pathway use a common
downstream signaling cascade, which emerges to reside in
either a protein kinase C–mediated or direct opening of
adenosine triphosphate potassium (KATP) channels, thereby
preventing intracellular calcium overload.24,25 This finding,
together with the previous evidence for the role of DADLE in
the context of natural hibernation, indicated that the two
seemingly unrelated entities of natural hibernation and
ischemic preconditioning share signaling pathways involving
peripheral δ-opioid receptor activation. 
In a recent report by Kevelaitis and colleagues,7 both phe-
nomena were addressed in a single experimental study. Their
work was directed to the cardioprotective transduction path-
way further downstream from the activation of the δ-opioid
receptor. Evidence is provided that opening of the KATP chan-
nels in fact is its final effector, since pretreatment with the
KATP-channel blocker glibenclamide abolished the organ pro-
tective effects of both preconditioning and DADLE.
Figure 2. Recovery rates of aortic flow (in percentage of preischemic value). IPC, Ischemic preconditioning;
DADLE, D-Ala2-D-Leu5 enkephalin. *P = .038 versus “control IPC+”; means of groups “control IPC+,” “DADLE IPC-,”
and “DADLE IPC+” were different from group means of all other groups (P < .001).
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Unlike previous studies, the present work focused on the
functional consequences of both treatments, because from a
clinical standpoint the quality of any kind of myocardial protec-
tion is estimated by its potential to regenerate postischemic car-
diac function. In view of the limitations of nonworking heart
systems, including the absence of external work to be performed
against constant afterload and reduced oxygen requirements, the
isolated working rat heart model was used. A protocol of unpro-
tected global ischemia at moderate hypothermia was used.
We found that both protective measures, administration of
DADLE and ischemic preconditioning, similarly improve the
postischemic regeneration of the parameters “aortic flow” and
“cardiac output.” Pretreatment with DADLE before ischemic
preconditioning further enhanced functional recovery, sug-
gesting that the two measures have additive effects. Even
though the δ-opioid receptor is thought to be involved in both
instances, it is conceivable that activation of another protec-
tive pathway that is not shared between ischemic precondi-
tioning and treatment with DADLE accounts for additional
protection. In this context, it warrants consideration that the
beneficial effects of ischemic preconditioning may be induced
not only by receptor-mediated pathways. Thus, it appears
that oxygen-derived free radicals released during brief
ischemia/reperfusion act as a nonreceptor trigger of precondi-
tioning, involving a phospholipase C– and/or D–mediated
mechanism.23 The other explanation may be related to the
dosage of DADLE selected in this study. It is thus possible
that the concentration of 1 mg/kg (usually considered to be a
standard opiate dosage) given systemically 1 hour before
organ retrieval was not high enough to activate myocardial δ-
opioid receptors quantitatively, thereby leaving an aliquot of
receptors arousable for other appropriate signals such as the
preconditioning signal. Dosage and the time interval between
DADLE administration and isolated heart perfusion were
selected according to previous evidence that (1) this concen-
tration was effective in the rabbit heart, (2) pretreatment at a
DADLE dosage of 10 mg/kg instead of 1 mg/kg resulted in
pronounced bradycardia in our own pilot experiments, and (3)
the protective effects of hibernation induction triggers similar
to DADLE were lost when the time interval between in vivo
preperfusion and organ ischemia was less than 1 hour.9
Pretreatment with naloxone abrogated the improvement of
aortic flow regeneration that was observed with DADLE,
ischemic preconditioning, or the combination thereof. This
observation further supports findings of Schultz, Hsu, and
Gross3 obtained in intact rat hearts, who reported that ischemic
preconditioning and morphine-induced cardioprotection
involve the δ-opioid receptor. 
The recovery rates of “aortic flow” were constantly lower
than those of other parameters (maximum left ventricular
developed pressure and dP/dtmax). This dissociation is
explained by the fact that isolated hearts can generate a con-
siderable rate of recovery in developed pressure, which still
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 5   991
may not be high enough to overcome the afterload imposed
in a working heart system. 
The CK release pattern during early reperfusion in the
Langendorff mode matched to the recovery rates of aortic
flow inasmuch as CK values observed with the combination
of DADLE and ischemic preconditioning were reduced,
when compared with untreated control hearts (P = .001).
This would suggest, therefore, that the improved functional
recovery induced by DADLE before ischemic precondition-
ing was a result of enhanced cell salvage. With naloxone
pretreatment no such difference was measured in compari-
son with untreated controls, a finding that corresponds to the
abrogation of functional improvement. The decrease in CK
release that was observed in all experimental groups during
working heart reperfusion in comparison with the previous
Langendorff reperfusion reflects an “easing off” of the
immediate postischemic CK washout. This may be attrib-
uted to normalization of coronary flow in combination with
the regenerative effect of ongoing reperfusion.26,27
Limitations of the Study and Concluding Comments
There are many obvious differences between the isolated
perfused rat heart and the human heart in situ. The limita-
tions of this type include the lack of a physiologic periph-
eral component and aspects of metabolic, nervous, and
hormonal control, because aqueous solutions free of red
cells, protein, and fatty acids are used to perfuse the coro-
nary arteries. In addition, time of reperfusion is limited as is
the time for postischemic observations. 
Preperfusion with DADLE was conducted in the intact
animal, raising the possibility that the opioid receptors
involved could be either central or peripheral and, if periph-
eral, cardiac or noncardiac in location. However, the similar
beneficial results from previous studies in which in vitro
preperfusion of the heart with DADLE was used suggest
that in fact cardiac opioid receptors are involved.18 This
issue was further clarified by Aitchison and colleagues,28
who demonstrated that the opioid receptors mediating clas-
sic ischemic preconditioning are also cardiac and not
extracardiac. In view of this evidence, there is reason to
assume that cardiac rather than extracardiac opioid recep-
tors are involved in the current findings too. 
It is conceivable that the additive effects observed after
pretreatment with DADLE in combination with ischemic pre-
conditioning depend on the dosage of DADLE or its protocol
of administration. Thus, it remains to be determined whether
additive effects persist with higher nontoxic concentrations of
DADLE. However, we have observed that pretreatment with
DADLE and ischemic preconditioning similarly improve
postischemic cardiac regeneration in a clinically relevant and
functionally oriented experimental model. This finding ren-
ders the former treatment a theoretical alternative to classic
protocols of ischemic preconditioning. The search for such
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alternatives is of considerable relevance because safety con-
cerns about inflicting an ischemic insult to the heart have lim-
ited the clinical applicability of ischemic preconditioning so
far. In surgical practice, however, opioid receptor stimulation
before the ischemic interval may be less effective than
expected because of the widespread use of morphine and fen-
tanyl in anesthesia. As previous studies have shown, both
drugs may antagonize δ-opioid receptor–mediated effects
because they are µ-opioid receptor agonists, thus negating the
beneficial effects of δ-receptor–activating agents.29 On the
other hand, there is evidence that morphine itself has activity
at the δ1-receptor, which implies beneficial effects with
respect to myocardial protection.30 Conversely, the use of
agonist/antagonist drugs to achieve myocardial protection
could antagonize the analgesic effects of µ-active agents like
morphine or fentanyl. These potentially limiting aspects need
to be taken into account before opiates are used for such pur-
poses. In view of this, the recent results obtained with direct
potassium channel openers are promising.7 Our findings sup-
port the search for similar pharmacologic interventions
directed further downstream from the opioid receptor level,
because we observed that the activation of the δ-opioid recep-
tor–mediated pathway bears the potential to enhance the
postischemic functional regeneration of the heart. 
We express our gratitude to C. Abraham, PhD, our consultant
statistician for biostatistical review of the study.
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